Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6

Nature Structural and Molecular Biology

Volumn 22, Issue 9, 2015, Pages 703-711

  Park, Eunyoung ^a,b   Kim, Nayoung ^c,d   Ficarro, Scott B ^a   Zhang, Yi ^a   Lee, Byung I ^a,e   Cho, Ahye ^c,d   Kim, Kihong ^d   Park, Angela K J ^c,d   Park, Woong Yang ^c,d   Murray, Bradley ^f   Meyerson, Matthew ^a,b,f   Beroukhim, Rameen ^a,b,f   Marto, Jarrod A ^a,b   Cho, Jeonghee ^c,d   Eck, Michael J ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Samsung Medical Center   (South Korea)

^d Sungkyunkwan University   (South Korea)

^e National Cancer Center   (South Korea)

^f BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MIG6 PROTEIN; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; MIG-6 PROTEIN, HUMAN; PROTEIN BINDING; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME MECHANISM; ENZYME SUBSTRATE; GENE; GENE AMPLIFICATION; GENETIC CODE; GLIOMA; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; NEGATIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; ANTAGONISTS AND INHIBITORS; CHEMISTRY; GENE DELETION; GENETICS; METABOLISM; MOLECULAR MODEL; PATHOLOGY; PHOSPHORYLATION; PROTEIN CONFORMATION; PROTEIN PROCESSING; X RAY CRYSTALLOGRAPHY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CRYSTALLOGRAPHY, X-RAY; GENE DELETION; GLIOMA; HUMANS; MODELS, MOLECULAR; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; SRC-FAMILY KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 84941023704     PISSN: 15459993     EISSN: 15459985     Source Type: Journal    
DOI: 10.1038/nsmb.3074     Document Type: Article

References (59)

1. Fiorentino, L. et al. Inhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domain. Mol. Cell. Biol. 20, 7735-7750 (2000).
2. Hackel, P.O., Gishizky, M. & Ullrich, A. Mig-6 is a negative regulator of the epidermal growth factor receptor signal. Biol. Chem. 382, 1649-1662 (2001).
3. Xu, D., Makkinje, A. & Kyriakis, J.M. Gene 33 is an endogenous inhibitor of epidermal growth factor (EGF) receptor signaling and mediates dexamethasone-induced suppression of EGF function. J. Biol. Chem. 280, 2924-2933 (2005).
4. Segatto, O., Anastasi, S. & Alema, S. Regulation of epidermal growth factor receptor signalling by inducible feedback inhibitors. J. Cell Sci. 124, 1785-1793 (2011).
5. Fiorini, M. et al. Expression of RALT, a feedback inhibitor of ErbB receptors, is subjected to an integrated transcriptional and post-translational control. Oncogene 21, 6530-6539 (2002).
6. Zhang, Y.W. & Vande Woude, G.F. Mig-6, signal transduction, stress response and cancer. Cell Cycle 6, 507-513 (2007).
7. Anastasi, S., Baietti, M.F., Frosi, Y., Alema, S. & Segatto, O. The evolutionarily conserved EBR module of RALT/MIG6 mediates suppression of the EGFR catalytic activity. Oncogene 26, 7833-7846 (2007).
8. Zhang, X. et al. Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature 450, 741-744 (2007).
9. Descot, A. et al. Negative regulation of the EGFR-MAPK cascade by actin-MAL-mediated Mig6/Errf-1 induction. Mol. Cell 35, 291-304 (2009).
10. Frosi, Y. et al. A two-tiered mechanism of EGFR inhibition by RALT/MIG6 via kinase suppression and receptor degradation. J. Cell Biol. 189, 557-571 (2010).
11. Ying, H. et al. Mig-6 controls EGFR traffcking and suppresses gliomagenesis. Proc. Natl. Acad. Sci. USA 107, 6912-6917 (2010).
12. Ferby, I. et al. Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation. Nat. Med. 12, 568-573 (2006).
13. Zhang, Y.W. et al. Evidence that MIG-6 is a tumor-suppressor gene. Oncogene 26, 269-276 (2007).
14. Maity, T.K. et al. Loss of MIG6 accelerates initiation and progression of mutant epidermal growth factor receptor-driven lung adenocarcinoma. Cancer Discov (2015).
15. Anastasi, S. et al. Loss of RALT/MIG-6 expression in ERBB2-amplifed breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin. Oncogene 24, 4540-4548 (2005).
16. Makkinje, A. et al. Gene 33/Mig-6, a transcriptionally inducible adapter protein that binds GTP-Cdc42 and activates SAPK/JNK. A potential marker transcript for chronic pathologic conditions, such as diabetic nephropathy: possible role in the response to persistent stress. J. Biol. Chem. 275, 17838-17847 (2000).
17. Anastasi, S. et al. Feedback inhibition by RALT controls signal output by the ErbB network. Oncogene 22, 4221-4234 (2003).
18. Wang, Z. et al. Mechanistic insights into the activation of oncogenic forms of EGF receptor. Nat. Struct. Mol. Biol. 18, 1388-1393 (2011).
19. Lemmon, M.A. & Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 141, 1117-1134 (2010).
20. Kandoth, C. et al. Mutational landscape and signifcance across 12 major cancer types. Nature 502, 333-339 (2013).
21. Brennan, C.W. et al. The somatic genomic landscape of glioblastoma. Cell 155, 462-477 (2013).
22. Cancer Genome Atlas Research Network. Comprehensive molecular profling of lung adenocarcinoma. Nature 511, 543-550 (2014).
23. Sharma, S.V., Bell, D.W., Settleman, J. & Haber, D.A. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7, 169-181 (2007).
24. Mok, T.S. et al. Geftinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947-957 (2009).
25. Yu, H.A. & Pao, W. Targeted therapies: afatinib: new therapy option for EGFR-mutant lung cancer. Nat. Rev. Clin. Oncol. 10, 551-552 (2013).
26. Chong, C.R. & Janne, P.A. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat. Med. 19, 1389-1400 (2013).
27. Lee, J.C. et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med. 3, e485 (2006).
28. Francis, J.M. et al. EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. Cancer Discov. 4, 956-971 (2014).
29. Wong, A.J. et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc. Natl. Acad. Sci. USA 89, 2965-2969 (1992).
30. Verhaak, R.G. et al. Integrated genomic analysis identifes clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98-110 (2010).
31. Guha, U. et al. Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specifc alleles of EGFR and KRAS. Proc. Natl. Acad. Sci. USA 105, 14112-14117 (2008).
32. Wolf-Yadlin, A. et al. Effects of HER2 overexpression on cell signaling networks governing proliferation and migration. Mol. Syst. Biol. 2, 54 (2006).
33. Wang, Z. et al. Tyrosine phosphorylation of mig6 reduces its inhibition of the epidermal growth factor receptor. ACS Chem. Biol. 8, 2372-2376 (2013).
34. Ficarro, S.B. et al. Magnetic bead processor for rapid evaluation and optimization of parameters for phosphopeptide enrichment. Anal. Chem. 81, 4566-4575 (2009).
35. Guo, A. et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc. Natl. Acad. Sci. USA 105, 692-697 (2008).
36. Cho, J. et al. Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies. Cancer Res. 71, 7587-7596 (2011).
37. Greulich, H. et al. Oncogenic transformation by inhibitor-sensitive and-resistant EGFR mutants. PLoS Med. 2, e313 (2005).
38. Yasuda, H. et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci. Transl. Med. 5, 216ra177 (2013).
39. Galisteo, M.L., Yang, Y., Urena, J. & Schlessinger, J. Activation of the nonreceptor protein tyrosine kinase Ack by multiple extracellular stimuli. Proc. Natl. Acad. Sci. USA 103, 9796-9801 (2006).
40. Shen, F., Lin, Q., Gu, Y., Childress, C. & Yang, W. Activated Cdc42-associated kinase 1 is a component of EGF receptor signaling complex and regulates EGF receptor degradation. Mol. Biol. Cell 18, 732-742 (2007).
41. Muir, T.W., Sondhi, D. & Cole, P.A. Expressed protein ligation: a general method for protein engineering. Proc. Natl. Acad. Sci. USA 95, 6705-6710 (1998).
42. Silverman, R.B. Mechanism-based enzyme inactivators. Methods Enzymol. 249, 240-283 (1995).
43. Carpentier, J.L., White, M.F., Orci, L. & Kahn, R.C. Direct visualization of the phosphorylated epidermal growth factor receptor during its internalization in A-431 cells. J. Cell Biol. 105, 2751-2762 (1987).
44. Bose, R., Holbert, M.A., Pickin, K.A. & Cole, P.A. Protein tyrosine kinase-substrate interactions. Curr. Opin. Struct. Biol. 16, 668-675 (2006).
45. Bettegowda, C. et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 333, 1453-1455 (2011).
46. Zack, T.I. et al. Pan-cancer patterns of somatic copy number alteration. Nat. Genet. 45, 1134-1140 (2013).
47. Hopkins, S. et al. Mig6 is a sensor of EGF receptor inactivation that directly activates c-Abl to induce apoptosis during epithelial homeostasis. Dev. Cell 23, 547-559 (2012).
48. Bagchi, A. & Mills, A.A. The quest for the 1p36 tumor suppressor. Cancer Res. 68, 2551-2556 (2008).
49. Red Brewer, M. et al. Mechanism for activation of mutated epidermal growth factor receptors in lung cancer. Proc. Natl. Acad. Sci. USA 110, E3595-E3604 (2013).
50. Cho, J. et al. Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization. Cancer Res. 73, 6770-6779 (2013).
51. Adelmant, G. et al. in Sample Preparation in Biological Mass Spectrometry (eds. Ivanov A.R. & Lazarev, A.V.) 437-486 (Springer, 2011).
52. Ficarro, S.B. et al. Improved electrospray ionization effciency compensates for diminished chromatographic resolution and enables proteomics analysis of tyrosine signaling in embryonic stem cells. Anal. Chem. 81, 3440-3447 (2009).
53. Parikh, J.R. et al. multiplierz: an extensible API based desktop environment for proteomics data analysis. BMC Bioinformatics 10, 364 (2009).
54. Yuza, Y. et al. Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors. Cancer Biol. Ther. 6, 661-667 (2007).
55. Yun, C.H. et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11, 217-227 (2007).
56. Otwinowski, Z., Borek, D., Majewski, W. & Minor, W. Multiparametric scaling of diffraction intensities. Acta Crystallogr. A 59, 228-234 (2003).
57. Emsley, P., Lohkamp, B., Scott, W.G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501 (2010).
58. Adams, P.D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213-221 (2010).
59. Cancer Genome Atlas Research Network. et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N. Engl. J. Med. 372, 2481-2498 (2015).